Tardive dyskinesia (TD) is a severe side effect of traditional neuroleptics affecting a considerable number of schizophrenic patients. Accumulating evidence suggests the existence of a genetic disposition to TD and other extra pyramidal symptoms (EPS) most strongly linked to a ser/gly polymorphism in position 9 of the D3 dopamine receptor gene (DRD3). The Cebus apella monkey is the favored animal model to study TD and other EPS because of its high susceptibility to side effects of neuroleptics. We therefore determined the sequence of the DRD3 gene in this species and compared it with that of humans. We found that the highly TD susceptible C. apella monkey (n ¼ 21) carries the gly9/gly9 DRD3 genotype that has been associated with TD in humans. Contrarily, C. apella did not carry the ser23 5HT2C allele that has been reported to increase TD susceptibility in humans.
INTRODUCTION
Tardive dyskinesia (TD) is a severe involuntary movement disorder following long-term treatment with traditional neuroleptics. 1 Although there is evidence to suggest that genetic factors play a significant role in the development of this disorder, [2] [3] [4] [5] [6] the mechanisms underlying both the therapeutic and side effects of antipsychotic medication are poorly understood.
The predominant feature of antipsychotic drugs-in particular traditional neuroleptics-is a strong blockage of the dopamine receptors. Therefore, pharmacogenetic analysis of TD susceptibility has focused on polymorphisms in the dopamine pathway 7 and in particular on the dopamine receptor D3 (DRD3 8 ). Opposed to other dopamine receptors, DRD3 is localized in the limbic system that is believed to be important for the pathogenesis of schizophrenia, 8 and knockout of the DRD3 gene in mice leads to symptoms mimicking the extra pyramidal symptoms (EPS) caused by dopamine blockers. 9 Mutation scanning has revealed two nonsynonymous single nucleotide polymorphisms (SNP) in the DRD3 gene. The first and best described of these SNPs is located in exon 1 and is associated with a serine-to-glycine change, ser9gly. 10 Allele and genotype frequencies display considerable ethnic heterogeneity, with the genotype frequency for the serine-substituted D3 receptor ranging between 2% in Japanese controls and 52% in Italian controls and an average allele frequency of approx. 67% in Caucasians (see Dubertret et al 11 for review). Although the significance of this substitution in vivo remains unknown, it has been reported that the gly9 receptor in vitro binds dopamine with a seven-fold higher affinity than does the Ser9 receptor. 12 The gly9ser polymorphism has been examined in relation to both schizophrenia and TD. Whereas a possible link to schizophrenia is less clarified, 13 the original study reporting an association between the gly9 receptor and TD 14 has gained substantial support from a considerable number of subsequent studies. 15 The other known SNP in the human DRD3 gene is located in codon 38 (ala38thr), 16 but it has not been included in studies of the genetic predisposition to TD probably because it is rare among patients with schizophrenia as well as in the general population.
Other pathways have been investigated, although less intensively. These include the serotonin system, which is targeted by newer antipsychotic drugs, and the catabolic P450 system in the liver that affects steady-state serum concentration of antipsychootics during long-term medication (see Segman and Lerer 17 for review). Several studies have reported an association between genetic variation in these pathways and TD, while others have been unable to replicate these findings.
The C. apella is characterized by high susceptibility to TD affecting all or the vast majority of individuals, making this animal species the preferred experimental model to study these side effects. [18] [19] [20] Challenged with a typical antipsychotic, this monkey readily develops syndromes similar to acute dyskinesia in humans. 18, 19 Similarly, long-term treatment with neuroleptics leads to a chronic state resembling TD. [18] [19] [20] The acute effect of antipsychotics in C. apella previously sensitized to neuroleptics is predictive of the TD potential in humans and is generally assessed prior to initiating clinical trails. 21, 22 C. apella is at least five times more susceptible to develop EPS than humans. 23 So far, the genes determining the high TD susceptibility of C. apella have not been identified. Comparative studies of genes in humans and primates may help to provide knowledge about disease predisposing genes and their evolutionary history. To address the possible association between TD and the DRD3 gene, we have sequenced this gene in C. apella and compared its amino-acid sequence with that of other species including DRD3 of humans. In particular, we have assessed the ser9gly variation in 21 C. apella monkeys. Also, we have examined the 5HT2C gene in C. apella and determined the sequence around position +68, which has been shown to be polymorphic and potentially associated with TD in humans. 24 
RESULTS AND DISCUSSION
The C. apella DRD3 gene consists of six exons, corresponding to a coding segment of 1200 nucleotides. The sequences of these exons have been deposited under Genebank accession numbers AY079004-AY079009. The nucleotide identity between the coding region in the DRD3 gene of C. apella and the coding region of the corresponding human gene is 96.2%. Accordingly, there is a high degree of aminoacid homology between the DRD3 in C. apella and humans, that is only 12 of 400 amino acids differ, corresponding to an identity of 97% (Table 1 ). The high degree of evolutionary conservation between the DRD3 in C. apella and humans probably reflects its importance in essential brain functions.
Our study included 21 monkeys, representing four nonrelated populations of C. apella. All monkeys carry the DRD3 gly9 codon on both chromosomes, suggesting that the species C. apella is monomorphic for the amino acid associated with high susceptibility to TD in humans. The presence of glycine at position 9 in DRD3 of C. apella can be interpreted as support to the assumption of an association between gly9 DRD3 and TD.
A comparison of DRD3 in five mammalian species revealed that the amino acid at position 9 is the most variable in the receptor ( Table 2 ). The high degree of the interspecies variation of this amino acid suggests that it may not be subjected to evolutionary constraint. On the other hand, the receptors encoded by the human ser9 and gly9 alleles are reported to differ in their dopamine affinities, 12 indicating a role for this amino acid in the control of receptor action. The allele frequencies were determined in a Japanese population. 16 Tardive dyskinesia and the dopamine D3 receptor
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All Cebus monkeys were also monomorphic for threonine at position 38. The presence of thr38 in C. apella was surprising since alanine is conserved at this position in the sequences of the four mammalian species deposited in Genebank ( Table 2 ). The thr38 allele is found, however, at very low frequency in both healthy and schizophrenic Japanese individuals. 16 The ubiquitous presence of thr38 in the TD-sensitive Cebus monkey might indicate a role for thr38 in the susceptibility to this movement disorder. However, so far no studies have determined the thr38 frequency or performed polymorphism screening in schizophrenic patients suffering from TD.
Considering the very high TD susceptibility in C. apella, our study raises the possibility that one or more of the other 10 Cebus-specific amino acids (Table 1) are involved in the development of TD in this monkey species. None of these amino acids has been shown to be polymorphic in humans and their importance in TD susceptibility remains unknown.
Several polymorphic loci have been examined in relation to TD in humans, the most promising being those of the serotonin and P450 systems. 17 Whereas the CYP 2D6 and 1A2 genes are likely to affect serum concentration during chronic drug administration and thereby TD susceptibility, their influence may be of less importance to acutely induced EPS, including dyskinesia as observed experimentally in monkeys. The affinity for the serotonin receptors of new and less TD-inducing antipsychotics has prompted investigators to examine polymorphic loci in this neurotransmitter system. An intriguing study reported that the nonsynonymous substitution of G by C at position 68 of the 5HT2C gene (leading to a cys23ser conversion) additively contributed to increase TD susceptibility in individuals carrying gly9 DRD3. 24 We analyzed the 5HT2C gene in C. apella and found that all monkeys were homozygous for the cys23 allele. This finding suggests that high TD susceptibility can be present in a species in the absence of the serine version of the 5HT2C receptor and without the possible additive contribution of gly9 DRD3 and ser23 5HT2C reported in humans.
Our study illustrates how interspecies studies may provide insight into the pathoetiology of human disorders. Thus, patterns of divergences between species may be useful to assess the significance of genetic variation in putative human disease genes. Clearly, the genetic analysis of other primates of extreme phenotypes would be of interest; in particular, of a TD-resistant monkey species characterized as thoroughly as humans and Cebus, had one been described.
To our knowledge, this study represents the first use of interspecies covariation of pheno-and genotypes to gain information on genetic predisposition to psychiatric disorders. Using this approach, we provide support to the notion of an association between DRD3 gly9 and TD susceptibility, while our study fails to support the importance of 5HT2C ser23. Finally, the study raises the possibility that thr38 in the DRD3 gene is related to the susceptibility to TD.
MATERIALS AND METHODS
The study includes 21 C. apella monkeys. The monkeys derive from four different groups. One of these groups was caught in the wild about 25 years ago. The other groups of monkeys were born in captivity and purchased from distinct breeding stations over a period of 10 years. The animals are therefore considered to constitute at least four unrelated populations of C. apella.
The monkeys are housed in separate cages in a temperature-and humidity-regulated environment at a 12-h light/ dark cycle. All procedures are in compliance with Danish law regulating the use of animals in biomedical research and with the European Communities Council Directive of 24 November 1986 (86/609/EEC). The monkeys were anesthetized and 2.5 ml whole blood was drawn from a peripheral vein in the arm. High-molecular weight DNA was extracted from these samples.
Using polymerase chain reaction (PCR) the exons of the C. apella DRD3 gene were amplified from two not related monkeys. The primers for this purpose were designed on the basis of the human DRD3 gene (Genebank accesssion number: U25441). Amplified fragments of the C. apella DRD3 gene were subjected to agarose gel electrophoresis and then isolated from gel slices. The purified PCR fragments were sequenced. The sequences were identical in the two animals analyzed. Subsequently, the amino-acid sequence of C. apella DRD3 was deduced and compared with that of mouse, rat, African green monkey and man determined by other researchers and made accessible through the G protein database (http://www.gpcr.org).
To address the question whether the DRD3 ser9gly polymorphism is present in C. apella, a fragment encompassing this codon was amplified using primers with the sequences: Forw. 5 0 -GCTCTATCTCCAACTCTCACA-3 0 and Backw. 5 0 -AAGTCTACTCACCTCCAGGTA-3 0 . After treatment of the amplified product with MscI, the restriction fragments were subjected to agarose gel electrophoresis. Using this approach, serine at codon 9 would manifest itself in the appearance of three fragments, whereas the presence of a gly9 codon would confer an additional MscI site to the PCR fragment under examination. The polymorphic site associated with the ala38thr variation in the human DRD3 gene was also examined in C. apella. A 270 bp fragment containing the relevant codon was amplified using primers with the sequences: Forw: 5 0 -ATGGCACCTCTGAGTCAGCT-3 0 Tardive dyskinesia and the dopamine D3 receptor and Backw: 5 0 -CTCCAGGTATACCACCCAGG-3 0 . This fragment was treated with BsshI to distinguish between an alanine and a threonine codon.
To address the question whether the 5HT2C cys23ser polymorphism is present in C. apella, a fragment encompassing this codon was amplified and analyzed as described. 25 
